Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Latest Information Update: 23 Apr 2025
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Adverse reactions; Therapeutic Use
- 20 Apr 2025 Planned initiation date changed to 24Apr 2025.
- 27 Mar 2025 Planned initiation date changed from 26 Mar 2025 to 1 Apr 2025.
- 21 Mar 2025 Planned initiation date changed from 18 Mar 2025 to 26 Mar 2025.